- Endocrinology, Diabetes, and Metabolism
- Long-term management of Graves disease: a narrative review
-
Hyo-Jeong Kim
-
J Yeungnam Med Sci. 2023;40(1):12-22. Published online November 4, 2022
-
DOI: https://doi.org/10.12701/jyms.2022.00444
-
-
19,425
View
-
584
Download
-
5
Web of Science
-
7
Crossref
-
Abstract
PDF
- Graves disease (GD) is the most common cause of hyperthyroidism, accounting for more than 90% of cases in Korea. Patients with GD are treated with any of the following: antithyroid drugs (ATDs), radioactive iodine (RAI) therapy, or thyroidectomy. Most patients begin treatment with ATDs, and clinical guidelines suggest that the appropriate treatment period is 12 to 18 months. While RAI treatment and surgery manage thyrotoxicosis by destroying or removing thyroid tissue, ATDs control thyrotoxicosis by inhibiting thyroid hormone synthesis and preserving the thyroid gland. Although ATDs efficiently control thyrotoxicosis symptoms, they do not correct the main etiology of GD; therefore, frequent relapses can follow. Recently, a large amount of data has been collected on long-term ATDs for GD, and low-dose methimazole (MMZ) is expected to be a good option for remission. For the long-term management of recurrent GD, it is important to induce remission by evaluating the patient’s drug response, stopping ATDs at an appropriate time, and actively switching to surgery or RAI therapy, if indicated. Continuing drug treatment for an extended time is now encouraged in patients with a high possibility of remission with low-dose MMZ. It is also important to pay attention to the quality of life of the patients. This review aimed to summarize the appropriate treatment methods and timing of treatment transition in patients who relapsed several times while receiving treatment for GD.
-
Citations
Citations to this article as recorded by 
- A 30-year-old male patient who experienced recurring weakness in bilateral upper and lower extremities: a clinical vignette
Soo Hyun Ahn, Mathieu Boudier-Revéret, Seoyon Yang, Min Cheol Chang Journal of Yeungnam Medical Science.2025; 42: 27. CrossRef - Outcomes of Fixed-Dose Radioactive Iodine Therapy in Hyperthyroidism and Optimization of Follow-Up After Treatment Failure With Low-Dose Antithyroid Medication
Panita Kantikool, Naphat Buraphanawibun Cureus.2025;[Epub] CrossRef - Hub genes and key pathways of Graves’ disease: bioinformatics analysis and validation
Duan-rong Zhuang, Xin Hu, Hui-bin Huang Hormones.2025;[Epub] CrossRef - Commentary: Azathioprine as an adjuvant therapy in severe Graves’ disease: a randomized controlled open-label clinical trial
Madhukar Mittal, Azher Rizvi Frontiers in Endocrinology.2024;[Epub] CrossRef - Total Thyroidectomy – A Cost-effective Alternative to Anti-Thyroid Drugs in the Management of Grave's Disease
Erivelto Volpi, Leonardo M. Volpi Clinical Thyroidology.2023; 35(5): 183. CrossRef - Evaluation of the Abbott Alinity i Thyroid-Stimulating Hormone Receptor Antibody (TRAb) Chemiluminescent Microparticle Immunoassay (CMIA)
Deborah J. W. Lee, Soon Kieng Phua, Yali Liang, Claire Chen, Tar-Choon Aw Diagnostics.2023; 13(16): 2707. CrossRef - Mechanisms and Treatment Options for Hyperthyroid-Induced Osteoporosis: A Narrative Review
Robert M Branstetter, Rahib K Islam, Collin A Toups, Amanda N Parra, Zachary Lee, Shahab Ahmadzadeh, Giustino Varrassi, Sahar Shekoohi, Alan D Kaye Cureus.2023;[Epub] CrossRef
|